Shenzhen, China

Shuntao Luo

USPTO Granted Patents = 10 

Average Co-Inventor Count = 6.7

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Shenzhen, CN (2021 - 2023)
  • Guangdong, CN (2021 - 2023)

Company Filing History:


Years Active: 2021-2023

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Shuntao Luo: Innovator in Tumor-Specific Polypeptides

Introduction

Shuntao Luo is a prominent inventor based in Shenzhen, China, known for his significant contributions to the field of biotechnology. He holds a total of 10 patents, showcasing his innovative approach to medical science, particularly in cancer treatment.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Tumor-specific polypeptide and use thereof." This invention focuses on a novel tumor-specific polypeptide that exhibits a high affinity for HLA-A0201 and possesses the ability to induce cytotoxic T lymphocytes. The polypeptide is designed for diagnosing, preventing, and treating diseases, especially cancers associated with high expression or mutations in the TWISTNB gene. Another notable patent is related to a polypeptide and nucleic acid encoding it, which includes a comprehensive therapeutic method and diagnostic applications for detecting the polypeptide.

Career Highlights

Shuntao Luo has worked with notable companies in the biotechnology sector, including Genoimmune Therapeutics Co., Ltd. and BGI Shenzhen. His work in these organizations has contributed to advancements in cancer research and treatment methodologies.

Collaborations

He has collaborated with esteemed colleagues such as Yong Hou and Xiumei Lin, further enhancing the impact of his research and innovations in the field.

Conclusion

Shuntao Luo's work exemplifies the intersection of innovation and medical science, particularly in the development of targeted therapies for cancer. His contributions continue to pave the way for advancements in tumor diagnosis and treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…